Health Care [ 6/12 ] | Pharmaceuticals [ 27/75 ]
NASDAQ | Common Stock
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 5, 26 | -0.29 Increased by 0.00% | -0.32 Increased by +9.38% |
| Nov 4, 25 | -0.38 Decreased by -72.73% | -0.37 Decreased by -2.70% |
| Aug 5, 25 | -0.39 Decreased by -50.00% | -0.35 Decreased by -11.43% |
| May 5, 25 | -0.37 Increased by +46.80% | -0.28 Decreased by -33.00% |
| Mar 10, 25 | -0.29 Increased by +17.14% | -0.22 Decreased by -31.82% |
| Nov 5, 24 | -0.22 Decreased by -29.41% | -0.24 Increased by +8.33% |
| Aug 7, 24 | -0.26 Increased by 0.00% | -0.22 Decreased by -18.18% |
| May 7, 24 | -0.70 Decreased by -79.49% | -0.19 Decreased by -268.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 13.25 M Decreased by -22.43% | -64.65 M Decreased by -33.62% | Decreased by -487.95% Decreased by -72.26% |
| Sep 30, 25 | 14.54 M Decreased by -5.71% | -69.42 M Decreased by -90.22% | Decreased by -477.30% Decreased by -101.75% |
| Jun 30, 25 | 13.46 M Decreased by -18.14% | -67.81 M Decreased by -54.91% | Decreased by -503.86% Decreased by -89.23% |
| Mar 31, 25 | 10.70 M Decreased by -27.59% | -64.05 M Increased by +1.23% | Decreased by -598.74% Decreased by -36.41% |
| Dec 31, 24 | 17.08 M Increased by +15.41% | -48.39 M Decreased by -65.60% | Decreased by -283.27% Decreased by -43.49% |
| Sep 30, 24 | 15.43 M Increased by +2.28% | -36.49 M Decreased by -6.97 K% | Decreased by -236.58% Decreased by -6.81 K% |
| Jun 30, 24 | 16.44 M Increased by +8.26% | -43.78 M Decreased by -111.67% | Decreased by -266.27% Decreased by -95.51% |
| Mar 31, 24 | 14.77 M Increased by +10.47% | -64.85 M Decreased by -113.89% | Decreased by -438.93% Decreased by -93.62% |